Keryx Biopharma Reports Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting

Keryx Biopharmaceuticals, Inc.

(the "Company") today announced that Phase 2 clinical results of Zerenex™ (ferric citrate coordination complex) in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with elevated serum phosphorus and iron deficiency anemia has been selected as a Late Breaking oral presentation at the National Kidney Foundation 2014 Spring Clinical Meeting, taking place April 22-26, 2014 in Las Vegas, NV. This presentation, entitled "Zerenex™ (Ferric Citrate) for the Treatment of Iron-Deficiency Anemia and Reduction of Serum Phosphate in Non-Dialysis Dependent CKD," will be made during the Late Breaking Session on Friday, April 25, 2014, from 9:30am - 11:00am PDT, by Dr. Geoffrey Block, Director of Clinical Research at Denver Nephrology and Co-Chairman for this study. In addition to the late-breaking oral presentation, the following four abstracts have also been selected for poster presentation during the meeting. * "Phosphorus Binding with Ferric Citrate is Associated with Fewer Hospitalizations and Reduced Hospitalization Costs," R. Rodby, poster number 422; * "Economic Impact of Ferric Citrate Versus Standard of Care for Hemodialysis Patients," S. Brunelli, poster number 156; * "Phosphorus Binding with Ferric Citrate Reduces Erythropoiesis-Stimulating Agent (ESA) and IV Iron Usage and Cost in Patients with ESRD," R. Rodby, poster number 415; and * "Oral Ferric Citrate Eliminates the Need for Intravenous (IV) Iron in Dialysis Patients," M. Sika, poster number 79. Posters will be presented in the Exhibit Hall on Wednesday, April 23, from 6:00pm-7:30pm PDT. Each of the above mentioned abstracts are currently available on the National Kidney Foundation's website: http://www.kidney.org/news/meetings/clinical/abstract/index.cfm.